Understand the source comparison
Best Peptides for Beard Growth: Compound Comparison
Before choosing a peptide protocol, understand that the evidence base varies dramatically. What follows is a structured comparison of the compounds with published data. CJC-1295 + Ipamorelin GHRH agonist + ghrelin mimetic. Synergistic GH pulse amplitude increa
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before choosing a peptide protocol, understand that the evidence base varies dramatically. What follows is a structured comparison of the compounds with published data.
- CJC-1295 + Ipamorelin
- GHRH agonist + ghrelin mimetic. Synergistic GH pulse amplitude increase
- Indirect: IGF-1 elevation shown to prolong anagen phase in dermal tissue studies
- 100–200mcg each, subcutaneous, before bed 5–6 nights/week
- Strongest mechanistic rationale for follicle density improvement in androgen-permissive regions
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic. Raises GH without injection
- Same IGF-1 pathway as Ipamorelin; 60–80% sustained IGF-1 elevation at 25mg daily in Phase II trials
- 25mg oral, once daily, preferably evening to align with natural GH pulse
- Convenient oral alternative to injectable GH secretagogues; same follicle biology pathway
- TB-500 (Thymosin Beta-4)
- Actin-binding peptide. Promotes angiogenesis and tissue repair
- No direct follicle studies; mechanism does not intersect IGF-1 or androgen pathways
- 2–5mg subcutaneous, twice weekly
- No plausible biological mechanism for beard density; marketed without evidence
- GHK-Cu (Copper Peptide)
- Copper-binding tripeptide. Collagen synthesis, some anti-inflammatory properties
- Topical studies show improved wound healing; zero evidence for terminal follicle conversion
- Topical application 1–2%, once daily
- Skin health benefits possible; beard growth claims unsupported
- BPC-157
- Gastric peptide. Promotes angiogenesis and wound repair in GI tissue
- No hair biology studies; mechanism unrelated to follicle signalling
- 250–500mcg subcutaneous daily
- No intersection with DHT or IGF-1 pathways required for terminal follicle formation